NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $8.59 million for the quarter, compared to analyst estimates of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. The company's revenue was up 776.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.30) EPS. View Synergy Pharmaceuticals' Earnings History.

8 Wall Street analysts have issued twelve-month target prices for Synergy Pharmaceuticals' stock. Their predictions range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $8.8125 in the next twelve months. This suggests a possible upside of 356.6% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 54,868,105 shares, a drop of 12.8% from the June 15th total of 62,939,216 shares. Based on an average trading volume of 3,251,186 shares, the short-interest ratio is currently 16.9 days. Approximately 22.3% of the shares of the company are short sold. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Uniqure (QURE), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH) and Arrowhead Pharmaceuticals (ARWR).

News coverage about SGYP stock has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a coverage optimism score of 0.19 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.25 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.93.

Synergy Pharmaceuticals has a market capitalization of $468.81 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]